COVERAGE / ABBV / Healthcare

AbbVie Inc.

Pharmaceutical Preparations

COVERAGE STATUSACTIVE

DATA THROUGH2025-12-31

RESEARCH REPORTS2

SELECTED FILINGS1

Fundamental matrix

Latest / 2025-12-31 · Prior / 2024-12-31 · USD · Annual periods

Revenue

$61.16bn

Prior / $56.33bn

Change / +8.57%

SOURCE / 2026-02-20

Operating income

$15.08bn

Prior / $9.14bn

Change / +64.99%

SOURCE / 2026-02-20

Net income

$4.23bn

Prior / $4.28bn

Change / -1.22%

SOURCE / 2026-02-20

Diluted EPS

$2.36

Prior / $2.39

Change / -1.26%

SOURCE / 2026-02-20

Free cash flow

$17.82bn

Prior / $17.83bn

Change / -0.09%

SOURCE / 2026-02-20

Gross margin

Not available

Prior / Not available

Change / Unavailable

SOURCE / Not available

Operating margin

24.65%

Prior / 16.22%

Change / +8.43 pp

SOURCE / 2026-02-20

Return on avg. equity

15367.27%

Prior / 62.52%

Change / +15304.75 pp

SOURCE / 2026-02-20

Debt / equity

Not available

Prior / Not available

Change / Unavailable

SOURCE / Not available

ROE uses net income divided by average opening/closing equity. FCF = operating cash flow − selected capital expenditure. Debt/equity is unavailable because a verified interest-bearing-debt series is absent; total liabilities are not substituted for debt.

Inspect source tags, dates and accession numbers

{
  "revenue": {
    "start": "2025-01-01",
    "end": "2025-12-31",
    "val": 61160000000,
    "accn": "0001551152-26-000008",
    "fy": 2025,
    "fp": "FY",
    "form": "10-K",
    "filed": "2026-02-20",
    "frame": "CY2025",
    "tag": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
    "unit": "USD"
  },
  "netIncome": {
    "start": "2025-01-01",
    "end": "2025-12-31",
    "val": 4226000000,
    "accn": "0001551152-26-000008",
    "fy": 2025,
    "fp": "FY",
    "form": "10-K",
    "filed": "2026-02-20",
    "frame": "CY2025",
    "tag": "us-gaap:NetIncomeLoss",
    "unit": "USD"
  },
  "operatingIncome": {
    "start": "2025-01-01",
    "end": "2025-12-31",
    "val": 15075000000,
    "accn": "0001551152-26-000008",
    "fy": 2025,
    "fp": "FY",
    "form": "10-K",
    "filed": "2026-02-20",
    "frame": "CY2025",
    "tag": "us-gaap:OperatingIncomeLoss",
    "unit": "USD"
  },
  "eps": {
    "start": "2025-01-01",
    "end": "2025-12-31",
    "val": 2.36,
    "accn": "0001551152-26-000008",
    "fy": 2025,
    "fp": "FY",
    "form": "10-K",
    "filed": "2026-02-20",
    "frame": "CY2025",
    "tag": "us-gaap:EarningsPerShareDiluted",
    "unit": "USD/shares"
  },
  "operatingCashFlow": {
    "start": "2025-01-01",
    "end": "2025-12-31",
    "val": 19030000000,
    "accn": "0001551152-26-000008",
    "fy": 2025,
    "fp": "FY",
    "form": "10-K",
    "filed": "2026-02-20",
    "frame": "CY2025",
    "tag": "us-gaap:NetCashProvidedByUsedInOperatingActivities",
    "unit": "USD"
  },
  "capex": {
    "start": "2025-01-01",
    "end": "2025-12-31",
    "val": 1214000000,
    "accn": "0001551152-26-000008",
    "fy": 2025,
    "fp": "FY",
    "form": "10-K",
    "filed": "2026-02-20",
    "frame": "CY2025",
    "tag": "us-gaap:PaymentsToAcquirePropertyPlantAndEquipment",
    "unit": "USD"
  },
  "totalAssets": {
    "end": "2025-12-31",
    "val": 133960000000,
    "accn": "0001551152-26-000008",
    "fy": 2025,
    "fp": "FY",
    "form": "10-K",
    "filed": "2026-02-20",
    "tag": "us-gaap:Assets",
    "unit": "USD"
  },
  "shareholdersEquity": {
    "end": "2025-12-31",
    "val": -3270000000,
    "accn": "0001551152-26-000008",
    "fy": 2025,
    "fp": "FY",
    "form": "10-K",
    "filed": "2026-02-20",
    "tag": "us-gaap:StockholdersEquity",
    "unit": "USD"
  },
  "currentAssets": {
    "end": "2025-12-31",
    "val": 29062000000,
    "accn": "0001551152-26-000008",
    "fy": 2025,
    "fp": "FY",
    "form": "10-K",
    "filed": "2026-02-20",
    "tag": "us-gaap:AssetsCurrent",
    "unit": "USD"
  },
  "currentLiabilities": {
    "end": "2025-12-31",
    "val": 43289000000,
    "accn": "0001551152-26-000008",
    "fy": 2025,
    "fp": "FY",
    "form": "10-K",
    "filed": "2026-02-20",
    "tag": "us-gaap:LiabilitiesCurrent",
    "unit": "USD"
  }
}

Financial trend system

Annual financial trends are summarized in the accessible table below.

Annual figures / accessible table

Period end	Revenue	Net income	Free cash flow	EPS
2025-12-31	$61.16bn	$4.23bn	$17.82bn	$2.36
2024-12-31	$56.33bn	$4.28bn	$17.83bn	$2.39
2023-12-31	$54.32bn	$4.86bn	$22.06bn	$2.72
2022-12-31	$58.05bn	$11.84bn	$24.25bn	$6.63

Valuation context

Historical snapshot / 2026-09-17. Annual accounting period / 2025-12-31. Not current, TTM or forward valuation.

Dated ratios / eligible same-method sector sample
Measure	Snapshot value	Historical median	Sector median	Peer count
P/E	111.87x	Unavailable	27.08x	10
P/S	7.63x	Unavailable	6.63x	10
P/B	Unavailable	Unavailable	7.31x	8
EV / EBITDA	Unavailable	Unavailable	Unavailable	0
FCF yield	3.82%	Unavailable	3.88%	8

Annual denominators, not TTM or forward. Capitalization-based measures use estimated market capitalization from the dated quote snapshot. ADR/share-basis uncertainty is excluded. No comparable historical-multiple series or EV/EBITDA is available. Sector samples are equal-weight medians of this publication’s eligible covered companies; fiscal periods differ. No fair value or price target is implied.

Source: Yahoo Finance completed daily-bar snapshot; not live; market cap estimated using SEC shares at 2026-07-27 DAILY-BAR SOURCE ↗

Retained price snapshot and capitalization estimate

{
  "currentPrice": 264.02,
  "tradingDate": "2026-09-17",
  "marketCap": 466554305585.7,
  "source": "Yahoo Finance completed daily-bar snapshot; not live; market cap estimated using SEC shares at 2026-07-27"
}

Company & operating context

AbbVie Inc. is an SEC-reporting issuer listed on NYSE under ABBV. Its SEC industry description is Pharmaceutical Preparations. This profile organizes annual financial disclosures for research; sector labels are editorial groupings, not GICS classifications.

Drug developers, device manufacturers and care providers depend on distinct clinical, reimbursement and operating economics.

Segment-level revenue is not included in this standardized dataset. Consult the business and segment notes in the linked annual filing for the issuer’s actual reporting segments.

Filing timeline

10-KFILED / 2026-02-20PERIOD / 2025-12-31

ABBV filed this 10-K on 2026-02-20 for the reported period 2025-12-31. Reading focus: Product concentration, research investment, utilization, reimbursement and cash generation. This is a metadata-based reading guide; it does not assert that a particular event or risk change occurred in the document.

ORIGINAL SEC DISCLOSURE ↗

Research archive

HR-0004ABBVEarnings Review

ABBV: the annual earnings and cash-flow comparison ↗

AbbVie Inc.

Research abstract

A two-period review of ABBV revenue, profitability and cash conversion; reported revenue growth was 8.57%.

DATA THROUGH2025-12-312 MIN READPUBLISHED 2026-09-26

HR-0005ABBVCompany Research

ABBV: reading the FY2025 financial structure ↗

AbbVie Inc.

Research abstract

Annual revenue of USD 61.160 billion and net income of USD 4.226 billion for the period ended 2025-12-31.

DATA THROUGH2025-12-312 MIN READPUBLISHED 2026-09-26

Sector context & risk factors

Patent expiry, trial outcomes, reimbursement changes, litigation and acquisition integration.

Product concentration, research investment, utilization, reimbursement and cash generation.

HEALTHCARE SYSTEM ↗

Sources & dates

SEC annual filing · 2025-12-31 ↗Source date 2026-02-20
SEC annual filing · 2024-12-31 ↗Source date 2026-02-20
SEC annual filing · 2023-12-31 ↗Source date 2026-02-20
SEC annual filing · 2022-12-31 ↗Source date 2025-02-14
SEC issuer record ↗Source date 2026-09-18